Surgery Websites
Transplant Surgery »  Meet the Team »  Nephrology »  Sindhu Chandran, M.D.
Sindhu Chandran, M.D.

Sindhu Chandran, M.D.

Associate Professor of Medicine
Division of Nephrology
Department of Medicine

Contact Information

Academic Office
Phone: (415) 353-8374
Fax: (415) 353-8974
sindhu.chandran@ucsf.edu
Open Popup
  • All India Institute of Medical Sciences, M.B., B.S., 2001
  • University of Arizona, Intern, Medicine, 2004-2005
  • University of Arizona, Resident, Medicine, 2005-2007
  • Stanford University, Fellow, Medicine, 2007-2010
  • University of California, San Francisco, Fellow, Medicine, 2010-2011
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Nephrology Subspecialty
  • Chronic Kidney Disease
  • Immunosuppression for Kidney Transplantation
  • Kidney Transplantation
  • Living Kidney Donor Transplantation
  • Transplant Nephrology
  • Kidney Allocation
  • New-onset Diabetes After Transplantation (NODAT)
  • Protocol Kidney Biopsies

Dr. Chandran is an Assistant Professor at UCSF in the Department of Medicine, Division of Nephrology. A kidney and pancreas transplant specialist, Dr. Chandran is board certified in internal medicine and nephrology. She earned her medical degree at All India Institute of Medical Sciences, and completed her residency at the University of Arizona, a nephrology fellowship at Stanford University, and a Transplant Nephrology Fellowship at UCSF.  

MOST RECENT PUBLICATIONS FROM A TOTAL OF 44
Publications provided by UCSF Profiles, powered by CTSI.
  1. Flavio Vincenti, Sindhu Chandran, David Wojciechowski, Chung Leung, Erica Tavares, Qizhi Tang, Jun Shoji. SP729CLINICAL AND IMMUNOLOGIC PREDICTORS OF OUTCOME WITH A NOVEL BELATACEPT REGIMEN. Nephrology,Dialysis and Transplantation. 2018 May 1; 33(suppl_1):i592-i592. View in PubMed
  2. Flavio Vincenti, Sindhu Chandran, David Wojciechowski, Chung Leung, Erica Tavares, Qizhi Tang, Jun Shoji. SP729CLINICAL AND IMMUNOLOGIC PREDICTORS OF OUTCOME WITH A NOVEL BELATACEPT REGIMEN. . 2018 May 1; 33(suppl_1):i592-i592. View in PubMed
  3. Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. Transplant Proc. 2017 Oct; 49(8):1773-1778. View in PubMed
  4. Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants. Am J Transplant. 2017 Nov; 17(11):2945-2954. View in PubMed
  5. Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. Clin Transplant. 2017 Sep; 31(9). View in PubMed
  6. View All Publications

 

Site Directory
    X